Lv3
230 积分 2025-04-22 加入
Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC
56分钟前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
1小时前
已完结
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
1小时前
已完结
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
10天前
已完结
Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
14天前
已完结
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
16天前
已完结
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
19天前
已完结
Surrogate Endpoints in Regulatory Decision‐Making
19天前
已完结
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
20天前
已完结
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
20天前
已完结
皖公网安备34019202002308
